{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:14:50Z","timestamp":1780348490728,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A simple, rapid, sensitive, and cost-effective green solvent-assisted reverse-phase high-performance liquid chromatographic technique, coupled with a photodiode array detector, was developed and validated for the estimation of piroxicam (PRXM). The chromatographic separation was achieved by using a C-18 (250 \u00d7 4.6) mm, 5-\u03bcm stationary phase and a mobile phase consisting of methanol and 0.1% ortho-phosphoric acid in water in a ratio of (80:20) v\/v at a flow rate of 1\u00a0ml\/min. The detection was carried out at a wavelength of 254\u00a0nm with a constant injection volume of 10\u00a0\u03bcL throughout the analysis. The calibration curve was observed to be linear over the optimum concentration range of 50\u2013300\u00a0\u03bcg\u00a0mL\u22121, with an R2 value of 0.9995. The developed method was validated as per the International Council for Harmonisation (ICH) Q2 (R1) guideline. Various parameters like selectivity\/specificity, accuracy\/recovery, linearity, precision, detection limit, quantitation limit, robustness and stability of analyte in solution were performed for the method validation. The PRXM was evaluated under stressed conditions, including acidic, basic, oxidative, thermal and photolytic, as per ICH Q1 (R2) guidelines. Significant degradation was observed in acidic and basic degradation conditions. Conversely, the drug substance showed stability when exposed to oxidative, photolytic and thermal degradation conditions.<\/jats:p>","DOI":"10.1093\/chromsci\/bmae021","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:46:34Z","timestamp":1713696394000},"source":"Crossref","is-referenced-by-count":6,"title":["Development and Validation of Fast and Sensitive RP-HPLC Stability-Indicating Method for Quantification of Piroxicam in Bulk Drug"],"prefix":"10.1093","volume":"63","author":[{"given":"Vikas","family":"Chauhan","sequence":"first","affiliation":[{"name":"KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR , Ghaziabad 201206 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Grover","sequence":"additional","affiliation":[{"name":"KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR , Ghaziabad 201206 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Natural Product and Medicinal Chemistry Division , Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu 180001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nims Institute of Pharmacy, Nims University Rajasthan , Jaipur Delhi Highway, Jaipur, Rajasthan, 303121 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR , Ghaziabad 201206 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"2","key":"2025010912420420100_ref1","first-page":"811","article-title":"Preformulation study of piroxicam","volume":"10","author":"Bachhav","year":"2019","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"key":"2025010912420420100_ref2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nrd1523","article-title":"The role of the medicinal chemist in drug discovery \u2014 then and now","volume":"3","author":"Lombardino","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"key":"2025010912420420100_ref3","volume-title":"Proceedings of International Conference on Harmonization","year":"2005"},{"issue":"2","key":"2025010912420420100_ref4","first-page":"12","article-title":"HPLC: Isocratic or gradient elution and assessment of linearity in analytical methods","volume":"3","author":"Shrivastava","year":"2012","journal-title":"Journal of Advanced Scientific Research"},{"issue":"2","key":"2025010912420420100_ref5","first-page":"30","article-title":"An overview on HPLC method development, optimization and validation process for drug analysis","volume":"2","author":"Kumar","year":"2015","journal-title":"The Pharmaceutical and Chemical Journal"},{"issue":"4","key":"2025010912420420100_ref6","first-page":"76","article-title":"A review: HPLC method development and validation","volume":"5","author":"Bharadwaj","year":"2015","journal-title":"International Journal of Analytical and Bioanalytical Chemistry"},{"key":"2025010912420420100_ref7","volume-title":"The United States Pharmacopeia 36th and The National Formulary 27th, The United States Pharmacopoeial Convention","year":"2010"},{"key":"2025010912420420100_ref8","first-page":"1","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","author":"ICH","year":"2005"},{"key":"2025010912420420100_ref9","volume-title":"A Guide to Validation in HPLC","author":"Hearn","year":"1992"},{"key":"2025010912420420100_ref10","volume-title":"International Conference on Harmonization","author":"ICH","year":"1995"},{"issue":"4","key":"2025010912420420100_ref11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5958\/2231-5675.2016.00030.2","article-title":"Development and validation of stability indicating RP-HPLC method for Empagliflozin","volume":"6","author":"Patil","year":"2016","journal-title":"Asian Journal of Pharmaceutical Analysis"},{"key":"2025010912420420100_ref12","first-page":"329","volume-title":"Drugs and the Pharmaceutical Sciences","author":"Hong","year":"2000"},{"key":"2025010912420420100_ref13","volume-title":"International Conference on Harmonization","author":"ICH","year":"1996"},{"issue":"1","key":"2025010912420420100_ref14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1573412915666190906142536","article-title":"Metabolite detection and profiling using analytical methods","volume":"17","author":"Mehta","year":"2021","journal-title":"Current Pharmaceutical Analysis"},{"issue":"6","key":"2025010912420420100_ref15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.36468\/pharmaceutical-sciences.727","article-title":"Development and validation of novel and highly sensitive stability indicating reverse phase ultra performance liquid chromatography method for quantification of Ibrutinib and its ten degradation products","volume":"82","author":"Mehta","year":"2020","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"key":"2025010912420420100_ref16","doi-asserted-by":"crossref","first-page":"113768","DOI":"10.1016\/j.jpba.2020.113768","article-title":"LC and LC\u2013MS\/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway","volume":"194","author":"Mehta","year":"2021","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"5\u20136","key":"2025010912420420100_ref17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/10826076.2021.1906271","article-title":"Identification and characterization of new degradation products of belinostat using UHPLC-Q-TOF-MS\/MS and in silico toxicity prediction","volume":"44","author":"Mehta","year":"2021","journal-title":"Journal of Liquid Chromatography & Related Technologies"},{"key":"2025010912420420100_ref18","doi-asserted-by":"crossref","first-page":"114351","DOI":"10.1016\/j.jpba.2021.114351","article-title":"LC-MS\/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway","volume":"206","author":"Grover","year":"2021","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"1","key":"2025010912420420100_ref19","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5530\/ijper.56.1s.43","article-title":"Identification and characterization of in vitro metabolites of belinostat by rat liver microsomes using ultra performance liquid chromatography coupled with tandem mass spectrometry","volume":"56","author":"Grover","year":"2022","journal-title":"Indian Journal Of Pharmaceutical Education And Research"},{"issue":"3","key":"2025010912420420100_ref20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.36468\/pharmaceutical-sciences.971","article-title":"Identification and characterization of in vitro metabolites of Ibrutinib by rat liver microsomes using ultra-performance liquid chromatography coupled with tandem mass spectrometry","volume":"84","author":"Grover","year":"2022","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"key":"2025010912420420100_ref21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.5530\/ijper.56.3.142","article-title":"Development and validation of novel and highly sensitive stabilityindicating reverse phase UPLC method for quantification of Dabrafenib and its ten degradation products","volume":"56","author":"Grover","year":"2022","journal-title":"Indian Journal Of Pharmaceutical Education And Research"},{"key":"2025010912420420100_ref22","first-page":"1206","article-title":"Development and validation of a stability-indicating method for neostigmine bromide: separation, identification and characterization of degradation product using LC-MS and ESI-Q-TOF-MS\/MS","volume":"56","author":"Makkar","year":"2022","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"key":"2025010912420420100_ref23","doi-asserted-by":"crossref","first-page":"115045","DOI":"10.1016\/j.jpba.2022.115045","article-title":"Identification and characterization of forced degradation products of sertraline hydrochloride using UPLC, ultra-high-performance liquid chromatography-quadrupole-time of flight mass spectrometry (UHPLC-Q-TOF\/MS\/MS) and NMR","volume":"221","author":"Grover","year":"2022","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2025010912420420100_ref24","doi-asserted-by":"crossref","first-page":"115119","DOI":"10.1016\/j.jpba.2022.115119","article-title":"LC and LC-MS\/MS studies for identification and characterization of degradation products of d-tubocurarine chloride","volume":"223","author":"Grover","year":"2022","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"3","key":"2025010912420420100_ref25","first-page":"464","article-title":"Rapid analytical method development and validation of piroxicam by RP-HPLC","volume":"3","author":"Madhukar","year":"2011","journal-title":"Journal of Chemical and Pharmaceutical Research"},{"issue":"2","key":"2025010912420420100_ref26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.22456\/2527-2616.108512","article-title":"Pharmacopoeial HPLC methodology improvement: a case study of piroxicam","volume":"4","author":"Caet","year":"2020","journal-title":"Drug Analytical Research"},{"issue":"4","key":"2025010912420420100_ref27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.37358\/RC.17.4.5534","article-title":"Fast HPLC method for the determination of piroxicam and its application to stability study","volume":"68","author":"Panainte","year":"2017","journal-title":"Revista de Chimie"},{"issue":"1","key":"2025010912420420100_ref28","first-page":"123","article-title":"The development and validation of a rapid HPLC method for determination of piroxicam","volume":"63","author":"Dragomiroiu","year":"2015","journal-title":"Farm\u00e1cia"},{"issue":"6","key":"2025010912420420100_ref29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0731-7085(02)00025-0","article-title":"LC determination of piroxicam in human plasma","volume":"28","author":"Dadashzadeh","year":"2002","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/63\/1\/bmae021\/57402380\/bmae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/63\/1\/bmae021\/57402380\/bmae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:14:34Z","timestamp":1736428474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/doi\/10.1093\/chromsci\/bmae021\/7664601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmae021","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,5,4]]},"article-number":"bmae021"}}